Mallinckrodt (MNK) Announced Data Analysis on Terlipressin Presented at The Liver Meeting
- Top 10 News for 12/2: Crude Rips on OPEC Cut; Starbucks' Schultz Steps Down; Nonfarm Payrolls Flat in Nov.
- Unemployment Rate Drops to 4.6%
- Bond yields slip on U.S. jobs data, euro steady before Italy vote
- Alibaba (BABA) Founder Jack Ma Discuss Plans to Retire; 'I Don't Want to Die at the Office'
- Starbucks Coffee (SBUX) CEO Howard Schultz to Step Down, Appointed Executive Chairman; Kevin Johnson New CEO
Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.
Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, today announced results of a post-hoc analysis of terlipressin clinical trial data presented at The Liver Meeting®1 — the 67th Annual Meeting of the American Association for the Study of Liver Diseases, held Nov. 11–15, 2016 in Boston, Mass.
Terlipressin is being investigated for the treatment of HRS-1, an acute, rare and life-threatening condition requiring hospitalization, with currently no approved therapy in the U.S. or Canada. Terlipressin is approved for use in countries outside the U.S., including several in Europe.2,3,4,5
The Mallinckrodt-sponsored analysis, titled "Time for a New, More Inclusive Endpoint for Treatment of HRS-1? Small Changes in SCr of >20% Are Equivalent to HRS Reversal in Predicting Survival and Need for Renal Replacement Therapy During Treatment of HRS-1 With Terlipressin and Albumin," analyzed findings from the largest prospective data set from two previously completed [and published] studies evaluating terlipressin used in patients with HRS-1.6,7 Data were available for 308 patients with well-characterized HRS-1 from the two studies.
"Patients diagnosed with HRS-1 typically have a very poor prognosis, and there is a significant unmet need for an approved treatment," said Steven Romano, M.D., Chief Scientific Officer and Executive Vice President, Mallinckrodt. "This analysis underscores the clinical relevance of improvement in renal function in HRS-1 patients and supports our ongoing CONFIRM clinical trial,8 which is evaluating terlipressin as a potentially important therapy for U.S. patients."
Study MethodsData were analyzed for the predictive value of HRS-1 reversal (20% or 30% improvement in SCr) for survival and the use of Renal Replacement Therapy (RRT). Positive predictive value (PPV), negative predictive value (NPV), accuracy, sensitivity, and specificity were determined using standard definitions. Receiver operator curves (ROCs) were generated for overall survival by improvement in SCr from baseline to the end of treatment and HRS-1 reversal by improvement in SCr from baseline to end of treatment. Youden's index as an estimate of optimal cutoff for the ROCs was derived using the standard formula (Youden index = sensitivity + specificity – 1).9
Study ResultsImprovement in SCr had similar PPV, NPV, sensitivity, and specificity as HRS-1 reversal in predicting survival; HRS-1 reversal and improvement in SCr were similarly accurate in predicting the use of RRT. The number of patients achieving at least a 20% improvement in SCr was twice that of those achieving HRS-1 reversal in these two large studies. Small improvements in SCr of 15% were associated with increased survival; an improvement in SCr of 40% was the optimal cutoff for achieving HRS-1 reversal. More specific analysis results follow:
- 64 patients (21%) achieved HRS-1 reversal and 118 patients (38%) had at least a 20% fall in SCr.
- A 20% reduction in SCr gave predictive, sensitivity and specificity values that were similar to HRS-1 reversal for survival; 30% improvement in SCr did not increase accuracy.
- For RRT, results were similar; HRS-1 reversal was somewhat more accurate in predicting the use of RRT.
- HRS-1 reversal or improvement in SCr reduced the use of RRT from 50‒56% to 9‒12%.
- The number of patients achieving ≥20% improvement in SCr was twice that of those achieving HRS-1 reversal in these two large studies.
- The highest values for the Youden index for overall survival was 0.353, suggesting an optimal cutoff of 15% improvement in SCr from baseline to end of treatment. The highest value of the Youden index for HRS-1 reversal was 0.896, suggesting an optimal cutoff of 40% improvement in SCr from baseline to end of treatment.
Study LimitationsThis study is a post-hoc analysis of completed clinical trials.
The study abstract can be accessed here (abstract 2071). The poster is available on the Mallinckrodt website.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Shire's (SHPG) Phase 3 Investigational Study of VONVENDI Meets Primary Endpoint in Controlling Bleeding in Adults with VWD
- Digital Ally (DGLY) Announces Notable DVM-250 Recorder, FleetVu Services Order
- Senseonics Holdings (SENS) Enters Expanded Distribution Agreement with Roche (RHHBY)
Create E-mail Alert Related CategoriesCorporate News, FDA, Management Comments
Related EntitiesS1, Definitive Agreement
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!